- Home
- SND vs PRLD Comparison
SND vs PRLD Comparison
Compare SND & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SND
- PRLD
- Stock Information
- Founded
- SND 2011
- PRLD 2016
- Country
- SND United States
- PRLD United States
- Employees
- SND N/A
- PRLD N/A
- Industry
- SND Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- SND Industrials
- PRLD Health Care
- Exchange
- SND Nasdaq
- PRLD Nasdaq
- Market Cap
- SND 85.0M
- PRLD 69.1M
- IPO Year
- SND 2016
- PRLD 2020
- Fundamental
- Price
- SND $2.09
- PRLD $1.40
- Analyst Decision
- SND
- PRLD Strong Buy
- Analyst Count
- SND 0
- PRLD 3
- Target Price
- SND N/A
- PRLD $4.00
- AVG Volume (30 Days)
- SND 106.8K
- PRLD 284.3K
- Earning Date
- SND 11-11-2025
- PRLD 11-05-2025
- Dividend Yield
- SND 4.74%
- PRLD N/A
- EPS Growth
- SND N/A
- PRLD N/A
- EPS
- SND 0.02
- PRLD N/A
- Revenue
- SND $305,848,000.00
- PRLD $7,000,000.00
- Revenue This Year
- SND N/A
- PRLD N/A
- Revenue Next Year
- SND N/A
- PRLD N/A
- P/E Ratio
- SND $106.65
- PRLD N/A
- Revenue Growth
- SND 3.43
- PRLD N/A
- 52 Week Low
- SND $1.76
- PRLD $0.61
- 52 Week High
- SND $2.80
- PRLD $2.08
- Technical
- Relative Strength Index (RSI)
- SND 52.65
- PRLD 58.44
- Support Level
- SND $2.03
- PRLD $1.33
- Resistance Level
- SND $2.21
- PRLD $1.63
- Average True Range (ATR)
- SND 0.06
- PRLD 0.19
- MACD
- SND 0.00
- PRLD 0.02
- Stochastic Oscillator
- SND 36.84
- PRLD 45.12
About SND Smart Sand Inc.
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.